Literature DB >> 12116368

Flow cytometric detection of activated mouse integrin alphaIIbbeta3 with a novel monoclonal antibody.

Wolfgang Bergmeier1, Valerie Schulte, Gero Brockhoff, Ulrich Bier, Hubert Zirngibl, Bernhard Nieswandt.   

Abstract

BACKGROUND: Integrin alphaIIbbeta3 mediates platelet adhesion and aggregation and plays a crucial role in thrombosis and hemostasis. alphaIIbbeta3 is expressed in a low affinity state on resting platelets. Upon platelet activation, alphaIIbbeta3 shifts to a high affinity conformation that efficiently binds its ligands. On human platelets, the high affinity conformation of alphaIIbbeta3 is detected by the monoclonal antibody (mAb), PAC-1. However, a reagent with binding specificity to high affinity mouse alphaIIbbeta3 has not been described so far.
METHODS: A novel rat mAb directed against mouse alphaIIbbeta3 (JON/A) was generated and characterized. JON/A was conjugated with fluorescein isothiocyanate (JON/A(FITC)) or with R-phycoerythrin (JON/A(PE)) and used for flow cytometric analysis of mouse platelets.
RESULTS: Although JON/A(FITC) bound to resting and activated platelets, virtually no binding of the larger JON/A(PE) to resting platelets was detectable. However, strong binding of JON/A(PE) occurred on platelet activation in a dose-dependent manner. Binding of JON/A(PE) required extracellular free calcium and was irreversible, thereby stabilizing the high affinity conformation of alphaIIbbeta3.
CONCLUSION: JON/A(PE) is the first tool for direct assessment of integrin alphaIIbbeta3 activation in mice. Furthermore, JON/A(FITC) and JON/A(PE) provide the first examples of fluorescent antibody derivatives with identical antigenic specificity that allow the discrimination between the resting and the activated state of an integrin. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12116368     DOI: 10.1002/cyto.10114

Source DB:  PubMed          Journal:  Cytometry        ISSN: 0196-4763


  66 in total

1.  Rap1-Rac1 circuits potentiate platelet activation.

Authors:  Lucia Stefanini; Yacine Boulaftali; Timothy D Ouellette; Michael Holinstat; Laurent Désiré; Bertrand Leblond; Patrick Andre; Pamela B Conley; Wolfgang Bergmeier
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-11-10       Impact factor: 8.311

2.  Altered BCR signalling quality predisposes to autoimmune disease and a pre-diabetic state.

Authors:  Sebastian Königsberger; Jan Prodöhl; David Stegner; Vanessa Weis; Martin Andreas; Martin Stehling; Theresa Schumacher; Ruben Böhmer; Ina Thielmann; Judith M M van Eeuwijk; Bernhard Nieswandt; Friedemann Kiefer
Journal:  EMBO J       Date:  2012-06-22       Impact factor: 11.598

3.  P-selectin-mediated platelet-neutrophil aggregate formation activates neutrophils in mouse and human sickle cell disease.

Authors:  Renata Polanowska-Grabowska; Kori Wallace; Joshua J Field; Lanlin Chen; Melissa A Marshall; Robert Figler; Adrian R L Gear; Joel Linden
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-11-11       Impact factor: 8.311

4.  JAM-A protects from thrombosis by suppressing integrin αIIbβ3-dependent outside-in signaling in platelets.

Authors:  Meghna U Naik; Timothy J Stalker; Lawrence F Brass; Ulhas P Naik
Journal:  Blood       Date:  2012-01-23       Impact factor: 22.113

5.  The kinetics of αIIbβ3 activation determines the size and stability of thrombi in mice: implications for antiplatelet therapy.

Authors:  Moritz Stolla; Lucia Stefanini; R Claire Roden; Massiel Chavez; Jessica Hirsch; Teshell Greene; Timothy D Ouellette; Sean F Maloney; Scott L Diamond; Mortimer Poncz; Donna S Woulfe; Wolfgang Bergmeier
Journal:  Blood       Date:  2010-10-22       Impact factor: 22.113

6.  Deficiency of the tetraspanin CD63 associated with kidney pathology but normal lysosomal function.

Authors:  Jenny Schröder; Renate Lüllmann-Rauch; Nina Himmerkus; Irina Pleines; Bernhard Nieswandt; Zane Orinska; Friedrich Koch-Nolte; Bernd Schröder; Markus Bleich; Paul Saftig
Journal:  Mol Cell Biol       Date:  2008-12-15       Impact factor: 4.272

7.  A talin mutant that impairs talin-integrin binding in platelets decelerates αIIbβ3 activation without pathological bleeding.

Authors:  Lucia Stefanini; Feng Ye; Adam K Snider; Kasra Sarabakhsh; Raymond Piatt; David S Paul; Wolfgang Bergmeier; Brian G Petrich
Journal:  Blood       Date:  2014-02-28       Impact factor: 22.113

8.  The role of platelet adhesion receptor GPIbalpha far exceeds that of its main ligand, von Willebrand factor, in arterial thrombosis.

Authors:  Wolfgang Bergmeier; Crystal L Piffath; Tobias Goerge; Stephen M Cifuni; Zaverio M Ruggeri; Jerry Ware; Denisa D Wagner
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-30       Impact factor: 11.205

9.  Role of FcRgamma and factor XIIIA in coated platelet formation.

Authors:  Shawn M Jobe; Lorie Leo; Joshua S Eastvold; Gerhard Dickneite; Timothy L Ratliff; Steven R Lentz; Jorge Di Paola
Journal:  Blood       Date:  2005-08-16       Impact factor: 22.113

10.  p38 mitogen-activated protein kinase activation during platelet storage: consequences for platelet recovery and hemostatic function in vivo.

Authors:  Matthias Canault; Daniel Duerschmied; Alexander Brill; Lucia Stefanini; Daphne Schatzberg; Stephen M Cifuni; Wolfgang Bergmeier; Denisa D Wagner
Journal:  Blood       Date:  2009-11-30       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.